New treatment approach for advanced rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates a modified sandwich therapeutic regimen for patients with locally advanced rectal cancer. The study aims to optimize the treatment by reducing the intensity of postoperative chemotherapy while still utilizing neoadjuvant chemoradiotherapy. The goal is to improve both short-term and long-term efficacy while minimizing the side effects associated with traditional treatment methods. Participants will receive a combination of XELOX, Capecitabine monotherapy, and radiation as part of their treatment plan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Pathological confirmed rectal adenocarcinoma.

Clinical stage T3-4 or T any N1.With or without MRF positivity, with or without EMVI positivity, R0 resection is estimated.

No metastasis

No signs of intestinal obstruction; or intestinal obstruction has been relieved after proximal colostomy surgery.

Age ranged from 18 to 75

No previous radiotherapy，surgery and chemotherapy.

Exclusion Criteria:

Multiple primary tumor

Cachexy

Where it's running

• Zhenhai Lu
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Zhenhai Lu, Prof
• Email: luzhh@sysucc.org.cn
• Phone: +862087343584

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Irinotecan liposome with capecitabine and enronsubemab plus short-course radiotherapy before surgery for locally advanced rectal cancer

  This trial will test whether giving irinotecan liposome, capecitabine, and enronsubemab together with a short course of radiotherapy before surgery can better shrink locally advanced rectal cancer.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07281157

• Brachytherapy and Nivolumab Before Surgery for Rectal Cancer

  This small Phase II study tests whether targeted internal radiation therapy followed by two doses of nivolumab can be safely given before rectal cancer surgery to see if it helps the treatment work.

  Recruiting Phase 2 Sir Mortimer B. Davis - Jewish General Hospital · Montreal, Quebec · NCT07645118

• Camrelizumab with long-course chemoradiotherapy before surgery for locally advanced low rectal cancer (pMMR/MSS)

  This trial tests whether giving camrelizumab before and after long-course chemoradiotherapy helps people with locally advanced, pMMR/MSS low rectal cancer achieve a higher complete response and preserve the rectum.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07527026

• Galenos 2: Immunonutrition for head and neck, lung, and rectal cancer patients

  This trial tests whether taking a twice-daily galenic immunonutrition supplement can reduce side effects and help people with head and neck, lung, or locally advanced rectal cancer complete their cancer therapy.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Torino (TO) · NCT07514754

• GALENOS 1: Longitudinal nutrition and body composition in head and neck, lung, and rectal cancer patients

  This project will see how nutritional status and body composition change over time in adults with head and neck, lung, or locally advanced rectal cancer who are receiving standard anticancer treatments.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Torino (TO) · NCT07511413

• Short-Course RT with CAPOX and Tislelizumab vs Long-Course RT with Tislelizumab for Locally Advanced Rectal Cancer

  This study tests whether a shorter radiotherapy course with CAPOX chemotherapy and the PD-1 blocker tislelizumab works as well as the standard longer radiotherapy approach for locally advanced rectal cancer.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian and 2 other locations · NCT07469306

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.